Janku, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M., . . . Kurzrock, R. (2012). PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials.
Citação norma ChicagoJanku, Filip, et al. PIK3CA Mutation H1047R Is Associated With Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early Phase Clinical Trials. 2012.
Citação norma MLAJanku, Filip, et al. PIK3CA Mutation H1047R Is Associated With Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early Phase Clinical Trials. 2012.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.